

Substitute Form PTO-1449 (Modified)
 U.S. Department of Commerce
 Patent and Trademark Office

Attorney's Docket No.
 17109-013001 / 923

Application No.
 10/658,355

**List of Patents and Publications for Applicant's
 Information Disclosure Statement**

Applicant
 Rene Gantier et al.

Filing Date
 September 8, 2003

Group Art Unit
 1631

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/RSN/	AA	2004/0132977	07/08/04	Gantier et al.	530	351	09/08/03
↓	AB	2006/0195268	08/31/06	Vega	702	19	04/28/06
↓	AC	2006/0247170	11/02/06	Guyon et al.	514	12	06/26/06
↓	AD	2006/0251619	11/09/06	Borrelly et al.	424	85.6	05/04/06
↓	AE	2007/0172459	07/26/07	Gantier et al.	424	85.5	02/13/07

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/RSN/	AF	06/024547	03/09/06	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/RSN/	AG	Blazquez, J., et al., "Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM β -lactamases," Antimicrobial Agents and Chemotherapy, 31(1):145-149, (1995).
↓	AH	Martin, P., "Beyond the Next Generation of Therapeutic proteins," 10/2006, http://www.biotech-online.com/artimg/a20062123243425.PDF (accessed on 01/11/07) (3 pgs).
↓	AI	Media Release: "In Vivo Studies Provide Hope for Orally Available Protein Therapeutics," Paris, France and Boston, Massachusetts (USA), 04/26/06, http://www.prnewswire.co.uk/cgi/news/release?id=169343 (accessed on 01/08/07) (3 pgs).
↓	AJ	Media Release: "Nautilus Biotech and Angel Biotechnology Sign Agreement to Manufacture Belerofon(R) (Improved Alpha Interferon) for Phase I Clinical Trials," Paris, France and Northumberland, England, 12/06/04, http://www.prnewswire.co.uk/cgi/news/release?id=135767 (accessed on 01/08/07) (2 pgs).
↓	AK	Media Release: "Nautilus Biotech and HanAll Pharmaceutical Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea," Paris, France, 03/06/07, http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-06-2007/0004540099&EDATE= (accessed on 03/16/07) (3 pgs).
↓	AL	Media Release: "Nautilus Biotech announces IND filing for Belerofon®, its oral, long-lasting, Interferon-alpha drug," Paris, France, 02/27/07, http://www.nautilusbiotech.com/news_270207.html (accessed on 03/16/07) (3 pgs).
↓	AM	Media Release: "Nautilus Biotech Announces IND Filing for its Injectable Long-Lasting INTERFERON-alpha, BELEROFON(R)," Paris, France, 10/10/06, http://www.prnewswire.co.uk/cgi/news/release?id=181151 (accessed on 01/08/07) (2 pgs).


Examiner Signature

/Russell S. Negin/

Date Considered

11/28/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Rene Gantier et al.	
(37 CFR §1.98(b))		Filing Date September 8, 2003	Group Art Unit 1631
Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
/RSN/	AN	Media Release: "Nautilus Biotech Announces Progress on Belerofon, an Improved IFNalpha With Single Amino Acid Sequence Change, Designed to Reduce Frequency of Injection for Hepatitis C Chronic Infection and Cancer," Paris, France, 03/23/04, http://www.prnewswire.co.uk/cgi/news/release?id=119794 (accessed on 01/08/07) (2 pgs).	
	AO	Media Release: "Nautilus Biotech Announces Progress on Improved Interferon Beta for Multiple Sclerosis," Paris, France, 02/27/04, http://www.prnewswire.co.uk/cgi/news/release?id=118120 (accessed on 01/08/07) (1 pg).	
	AP	Media Release: "Nautilus Biotech Announces Progress on Next-Generation Interferon Gamma," Paris, France, 04/25/05, http://www.prnewswire.co.uk/cgi/news/release?id=144633 (accessed on 01/08/07) (1 pg).	
	AQ	Media Release: "Nautilus Biotech Moves its Next-Generation Long-Lasting Interferon Beta into Regulatory Preclinical Development," Paris, France, 07/18/05, http://www.prnewswire.co.uk/cgi/news/release?id=150268 (accessed on 01/08/07) (2 pgs).	
	AR	Media Release: "Nautilus Biotech: 'Next Generation Biopharmaceuticals (NGB),' Paris, France, 06/21/04, http://www.prnewswire.co.uk/cgi/news/release?id=125241 (accessed on 01/08/07) (1 pg).	
	AS	Media Release: "Nautilus Moves its Long-Lasting, High Availability Human Growth Hormone Into Formal Preclinical Development," Paris, France, 01/09/06, http://www.prnewswire.co.uk/cgi/news/release?id=161460 (accessed on 01/08/07) (2 pgs).	
	AT	Media Release: "Nautilus Reaches its First Milestone in Collaboration With Serono on Next-Generation Human Growth Hormone," Paris, France, 02/22/05, http://www.prnewswire.co.uk/cgi/news/release?id=140366 (accessed on 01/08/07) (1 pg).	
	AU	Media Release: "Serono and Nautilus Biotech Sign Worldwide Agreement to Develop and Commercialize a Next-Generation Growth Hormone," Geneva, Switzerland and Paris, France, 11/15/04, http://www.prnewswire.co.uk/cgi/news/release?id=134375 (accessed on 01/08/07) (2 pgs).	
↓	AV	Media Release: "Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies," 02/05/07, http://www.prnewswire.co.uk/cgi/news/release?id=189610 (accessed on 03/16/07) (2 pgs).	
	AW	Media Release: "Nautilus Biotech announces IND filing for Belerofon [®] , its oral, long-lasting, Interferon-alpha drug," Paris, France, 02/27/07, http://www.nautilusbiotech.com/news_270207.html (accessed on 03/16/07) (3 pgs). DUPLICATE	
/RSN/	AX	Media Release: "Nautilus Biotech begins Phase I clinical trial in the USA for subcutaneous Belerofon [®] , its long-lasting, Interferon-alpha drug," Paris, France, 04/02/07, http://www.nautilusbiotech.com/news_020407.html (accessed on 04/09/07) (3 pgs).	
/RSN/	AY	Media Release: "Nautilus Biotech and HanAll Pharmaceutical Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea," Paris, France, 03/06/07, http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-06-2007/0004540099&EDATE= (accessed on 03/16/07) (3 pgs).	
/RSN/	AZ	Media Release: "Nautilus Biotech receives FDA approval for Phase I clinical trial in the USA for oral Belerofon [®] , its long-lasting, Interferon-alpha drug," Paris, France, 05/14/07, http://www.nautilusbiotech.com/news_100507.html (accessed on 7/11/07) (3 pgs).	

Examiner Signature /Russell S. Negin/	Date Considered 11/28/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

IDS 9/4/07

Applicant : Rene Gantier et al.
 Serial No. : 10/658,355
 Filed : September 8, 2003

Attorney's Docket No.: 17109-013001 / 923
 Supplemental Information Disclosure Statement

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Copies of seven U.S. Office Actions (Documents III-IX), issued October 18, 2004; June 15, 2005; December 23, 2005; April 17, 2006; September 7, 2006; May 9, 2007; and August 30, 2007, respectively, in connection with co-owned U.S. Application Ser. No. 10/022,249 are provided. Copies of two European Examination Reports (Documents I and II), issued December 6, 2006 and July 31, 2007, respectively, in connection with European Patent Application No. 02798018.4 are provided. European Patent Application No. 02798018.4 corresponds to U.S. Application Ser. No. 10/022,249. The table below lists Documents I-IX and includes a column that provides a space next to the documents to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
<i>JK</i>	I	Copy of European Examination Report, issued December 6, 2006, in connection with European Patent Application No. 02798018.4
<i>JK</i>	II	Copy of European Examination Report, issued July 31, 2007, in connection with European Patent Application No. 02798018.4
<i>JK</i>	III	Copy of U.S. Office Action, issued October 18, 2004, in connection with U.S. Application Ser. No. 10/022,249
<i>JK</i>	IV	Copy of U.S. Office Action, issued June 15, 2005, in connection with U.S. Application Ser. No. 10/022,249
<i>JK</i>	V	Copy of U.S. Office Action, issued December 23, 2005, in connection with U.S. Application Ser. No. 10/022,249
<i>JK</i>	VI	Copy of U.S. Office Action, issued April 17, 2006, in connection with U.S. Application Ser. No. 10/022,249
<i>JK</i>	VII	Copy of U.S. Office Action, issued September 7, 2006, in connection with U.S. Application Ser. No. 10/022,249
<i>JK</i>	VIII	Copy of U.S. Office Action, issued May 9, 2007, in connection with U.S. Application Ser. No. 10/022,249
<i>JK</i>	IX	Copy of U.S. Office Action, issued August 30, 2007, in connection with U.S. Application Ser. No. 10/022,249

Handwritten signature



11/20/07

JOS 9/12/07

Applicant : Rene Gantier et al.
 Serial No. : 10/658,355
 Filed : September 8, 2003

Attorney's Docket No.: 17109-013001 / 923
 Supplemental Information Disclosure Statement

Provisional Applications Ser. Nos. 60/410,258 and 60/457,063, as does the instant application. The table below lists Documents I-II and includes a column that provides a space next to the documents to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	I	Copy of European Examination Report, issued August 2, 2005, in connection with European Patent Application No. 03748392.2
	II	Copy of European Examination Report, issued June 2, 2006, in connection with European Patent Application No. 03748392.2

In the European Examination Report, issued August 2, 2005 (Document I), five documents are cited: 1) US 5,223,409, 2) WO 01/61344, 3) Manetti et al., "Design and realization of a tailor-made enzyme to modify the molecular recognition of 2-arylpropionic esters by *Candida rugosa* lipase," *Biochem. Biophys. Acta.* 1543(1):146-158 (2000), 4) Lewerenz et al., "Shared receptor components but distinct complexes for alpha and beta interferons," *J. Mol. Biol.* 282(3):585-599 (1998), and 5) WO 03/023032. Documents 1-5 are made of record in the instant application in Information Disclosure Statements, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed March 17, 2004 and November 8, 2004. In the European Examination Report, issued June 2, 2006 (Document II), three documents are cited: 1) US 6,013,478, 2) WO 95/23813, 3) WO 01/32844. Documents 1-3 are made of record in the instant application in Information Disclosure Statements, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed November 8, 2004 and January 20, 2005.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.



11/25/07